UNSPSC 51273011: Vadocaine

This classification denotes an anesthetic agent with the molecular formula C18H28N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OKA45SU1Q4, chemically known as (+-)-6-methoxy-2-methyl-1-piperidinepropiono-2,4-xylidide but generally known as vadocaine, which bears US NIH Compound Identifier 68912. European Medicines Agency schedules Vadocaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00002MIG.

UNSPSC 51273011 Vadocaine is a Commodity code, but the recent state and local procurement activity under this code does not align with its nominal scope. The three opportunities posted in 2026 involve naloxone, direct-to-manufacturer pharmacy programs, and generic multi-source pharmaceuticals and OTC products—none of which are vadocaine or local anesthetic injections. State and local procurement activity under this code shows minimal relevant recent action; the mismatch between the code's intended product category and what issuing bodies are actually purchasing under it suggests either a data classification issue or very limited state and local demand for vadocaine specifically.

The available opportunities originate from diverse issuing bodies spanning a county health department (Seminole County, Florida), a state health and human services agency (Texas HHS Commission), and a multistate cooperative purchasing vehicle (Minnesota Multistate Cooperative Purchasing Alliance serving Minnesota and Oregon). Geographic activity appears limited to Florida, Texas, and the upper Midwest, with no apparent concentration of repeat solicitation or demand signals. The Seminole County IFB (IFB60459723LAS, due July 26, 2023) sought naloxone and drug deactivation systems with quarterly deliveries; the Texas RFI (HHS0017013, posted April 3, 2026) requested vendor capabilities for direct-to-manufacturer prescription programs; and the MMCAP RFP (S1070000015802, due March 26, 2026) established contracts for generic pharmaceuticals and OTC products across authorized wholesalers. None represents sustained or growing state and local procurement of vadocaine. Absence of clear recent activity under this code suggests limited pursuit opportunity unless demand emerges from hospital systems, municipal health clinics, or emergency medical services—none of which appear in the current opportunity record.